The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the second half of 2026
Newsflash:
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the second half of 2026
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the second half of 2026
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, and product …
Listen Now
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor continued expanding globally
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected in the second half of 2026
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while combination cohorts continue
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?